Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis (Blood Cancer Journal, (2019), 9, 12, (97), 10.1038/s41408-019-0261-1)

Nirav N. Shah; Kwang Woo Ahn; Carlos Litovich; Anna Sureda; Mohamed A. Kharfan-Dabaja; Farrukh T. Awan; Siddhartha Ganguly; Usama Gergis; David Inwards; Reem Karmali; Alexsandr Lazaryan; Lazaros Lekakis; Pashna Munshi; Sunita Nathan; Ayman A. Saad; Melhem Solh; Amir Steinberg; Ravi Vij; William A. Wood; Timothy S. Fenske; Sonali Smith; Mehdi Hamadani

doi:10.1038/s41408-021-00472-w

Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis (Blood Cancer Journal, (2019), 9, 12, (97), 10.1038/s41408-019-0261-1)

Nirav N. Shah, Kwang Woo Ahn, Carlos Litovich, Anna Sureda, Mohamed A. Kharfan-Dabaja, Farrukh T. Awan, Siddhartha Ganguly, Usama Gergis, David Inwards, Reem Karmali, Alexsandr Lazaryan, Lazaros Lekakis, Pashna Munshi, Sunita Nathan, Ayman A. Saad, Melhem Solh, Amir Steinberg, Ravi Vij, William A. Wood, Timothy S. FenskeSonali Smith, Mehdi Hamadani^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Article number	82
Journal	Blood cancer journal
Volume	11
Issue number	4
DOIs	https://doi.org/10.1038/s41408-021-00472-w
State	Published - Apr 2021

Funding

CIBMTR Support List, The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/ Cooperative Agreement U24HL138660 from NHLBI and NCI; Grant R21HL140314 from NHBLI; Grant U01HL128568 from NHLBI; a contract HHSH250201700006C with Health Resources and Services Administration (HRSA/DHHS); Grants N00014-18-1-2888 and N00014-17-1-2850 from the Office of Naval Research HHSH250201700006C; grants from *Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; *Anthem, Inc.; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; Boston Children’s Hospital; *Bristol Myers Squibb Co.; *Celgene Corp.; Children’s Hospital of Los Angeles; *Chimerix, Inc.; *CSL Behring; *CytoSen Therapeutics, Inc.; Dana Farber Cancer Institute; *Daiichi Sankyo Co., Ltd.; Fred Hutchinson Cancer Research Center; *Gamida-Cell, Ltd.; Gilead Sciences, Inc.; *GlaxoSmithKline (GSK); HistoGenetics, Inc.; Immucor; Incyte Corporation; Janssen Biotech, Inc.; *Janssen Pharmaceuticals, Inc.; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; *Kite, a Gilead Company; *Magenta Therapeutics; Medac GmbH; The Medical College of Wisconsin; Mediware; Merck & Company, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Oncology; Novartis Pharmaceuticals Corporation; *Omeros Corporation; *Oncoimmune, Inc.; PCORI; *Pfizer, Inc.; *Phamacyclics, LLC; PIRCHE AG; *Regeneron Pharmaceuticals, Inc.; REGiMMUNE Corp.; *Sanofi Genzyme; *Seattle Genetics; *Shire; Sobi, Inc.; Spectrum Pharmaceuticals, Inc.; St. Baldrick’s Foundation; Swedish Orphan Biovitrum, Inc.; *Takeda Oncology; University of Minnesota; University of Pittsburgh; University of Texas-MD Anderson; University of Wisconsin-Madison and Viracor Eurofins. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA), or any other agency of the U.S. Government. *Corporate members: Kristina Jacobs for administrative support.

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41408-021-00472-w

Cite this

Shah, N. N., Ahn, K. W., Litovich, C., Sureda, A., Kharfan-Dabaja, M. A., Awan, F. T., Ganguly, S., Gergis, U., Inwards, D., Karmali, R., Lazaryan, A., Lekakis, L., Munshi, P., Nathan, S., Saad, A. A., Solh, M., Steinberg, A., Vij, R., Wood, W. A., ... Hamadani, M. (2021). Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis (Blood Cancer Journal, (2019), 9, 12, (97), 10.1038/s41408-019-0261-1). Blood cancer journal, 11(4), Article 82. https://doi.org/10.1038/s41408-021-00472-w

@article{4699b7202cdd4a9fb12e86fb1cbdb30f,

title = "Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis (Blood Cancer Journal, (2019), 9, 12, (97), 10.1038/s41408-019-0261-1)",

author = "Shah, {Nirav N.} and Ahn, {Kwang Woo} and Carlos Litovich and Anna Sureda and Kharfan-Dabaja, {Mohamed A.} and Awan, {Farrukh T.} and Siddhartha Ganguly and Usama Gergis and David Inwards and Reem Karmali and Alexsandr Lazaryan and Lazaros Lekakis and Pashna Munshi and Sunita Nathan and Saad, {Ayman A.} and Melhem Solh and Amir Steinberg and Ravi Vij and Wood, {William A.} and Fenske, {Timothy S.} and Sonali Smith and Mehdi Hamadani",

note = "Funding Information: CIBMTR Support List, The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/ Cooperative Agreement U24HL138660 from NHLBI and NCI; Grant R21HL140314 from NHBLI; Grant U01HL128568 from NHLBI; a contract HHSH250201700006C with Health Resources and Services Administration (HRSA/DHHS); Grants N00014-18-1-2888 and N00014-17-1-2850 from the Office of Naval Research HHSH250201700006C; grants from *Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; *Anthem, Inc.; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; Boston Children{\textquoteright}s Hospital; *Bristol Myers Squibb Co.; *Celgene Corp.; Children{\textquoteright}s Hospital of Los Angeles; *Chimerix, Inc.; *CSL Behring; *CytoSen Therapeutics, Inc.; Dana Farber Cancer Institute; *Daiichi Sankyo Co., Ltd.; Fred Hutchinson Cancer Research Center; *Gamida-Cell, Ltd.; Gilead Sciences, Inc.; *GlaxoSmithKline (GSK); HistoGenetics, Inc.; Immucor; Incyte Corporation; Janssen Biotech, Inc.; *Janssen Pharmaceuticals, Inc.; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; *Kite, a Gilead Company; *Magenta Therapeutics; Medac GmbH; The Medical College of Wisconsin; Mediware; Merck & Company, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Oncology; Novartis Pharmaceuticals Corporation; *Omeros Corporation; *Oncoimmune, Inc.; PCORI; *Pfizer, Inc.; *Phamacyclics, LLC; PIRCHE AG; *Regeneron Pharmaceuticals, Inc.; REGiMMUNE Corp.; *Sanofi Genzyme; *Seattle Genetics; *Shire; Sobi, Inc.; Spectrum Pharmaceuticals, Inc.; St. Baldrick{\textquoteright}s Foundation; Swedish Orphan Biovitrum, Inc.; *Takeda Oncology; University of Minnesota; University of Pittsburgh; University of Texas-MD Anderson; University of Wisconsin-Madison and Viracor Eurofins. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA), or any other agency of the U.S. Government. *Corporate members: Kristina Jacobs for administrative support.",

year = "2021",

month = apr,

doi = "10.1038/s41408-021-00472-w",

language = "English (US)",

volume = "11",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Springer Nature",

number = "4",

}

Shah, NN, Ahn, KW, Litovich, C, Sureda, A, Kharfan-Dabaja, MA, Awan, FT, Ganguly, S, Gergis, U, Inwards, D, Karmali, R, Lazaryan, A, Lekakis, L, Munshi, P, Nathan, S, Saad, AA, Solh, M, Steinberg, A, Vij, R, Wood, WA, Fenske, TS, Smith, S & Hamadani, M 2021, 'Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis (Blood Cancer Journal, (2019), 9, 12, (97), 10.1038/s41408-019-0261-1)', Blood cancer journal, vol. 11, no. 4, 82. https://doi.org/10.1038/s41408-021-00472-w

Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis (Blood Cancer Journal, (2019), 9, 12, (97), 10.1038/s41408-019-0261-1). / Shah, Nirav N.; Ahn, Kwang Woo; Litovich, Carlos et al.
In: Blood cancer journal, Vol. 11, No. 4, 82, 04.2021.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Correction

T2 - Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis (Blood Cancer Journal, (2019), 9, 12, (97), 10.1038/s41408-019-0261-1)

AU - Shah, Nirav N.

AU - Ahn, Kwang Woo

AU - Litovich, Carlos

AU - Sureda, Anna

AU - Kharfan-Dabaja, Mohamed A.

AU - Awan, Farrukh T.

AU - Ganguly, Siddhartha

AU - Gergis, Usama

AU - Inwards, David

AU - Karmali, Reem

AU - Lazaryan, Alexsandr

AU - Lekakis, Lazaros

AU - Munshi, Pashna

AU - Nathan, Sunita

AU - Saad, Ayman A.

AU - Solh, Melhem

AU - Steinberg, Amir

AU - Vij, Ravi

AU - Wood, William A.

AU - Fenske, Timothy S.

AU - Smith, Sonali

AU - Hamadani, Mehdi

N1 - Funding Information: CIBMTR Support List, The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/ Cooperative Agreement U24HL138660 from NHLBI and NCI; Grant R21HL140314 from NHBLI; Grant U01HL128568 from NHLBI; a contract HHSH250201700006C with Health Resources and Services Administration (HRSA/DHHS); Grants N00014-18-1-2888 and N00014-17-1-2850 from the Office of Naval Research HHSH250201700006C; grants from *Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; *Anthem, Inc.; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; Boston Children’s Hospital; *Bristol Myers Squibb Co.; *Celgene Corp.; Children’s Hospital of Los Angeles; *Chimerix, Inc.; *CSL Behring; *CytoSen Therapeutics, Inc.; Dana Farber Cancer Institute; *Daiichi Sankyo Co., Ltd.; Fred Hutchinson Cancer Research Center; *Gamida-Cell, Ltd.; Gilead Sciences, Inc.; *GlaxoSmithKline (GSK); HistoGenetics, Inc.; Immucor; Incyte Corporation; Janssen Biotech, Inc.; *Janssen Pharmaceuticals, Inc.; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; *Kite, a Gilead Company; *Magenta Therapeutics; Medac GmbH; The Medical College of Wisconsin; Mediware; Merck & Company, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Oncology; Novartis Pharmaceuticals Corporation; *Omeros Corporation; *Oncoimmune, Inc.; PCORI; *Pfizer, Inc.; *Phamacyclics, LLC; PIRCHE AG; *Regeneron Pharmaceuticals, Inc.; REGiMMUNE Corp.; *Sanofi Genzyme; *Seattle Genetics; *Shire; Sobi, Inc.; Spectrum Pharmaceuticals, Inc.; St. Baldrick’s Foundation; Swedish Orphan Biovitrum, Inc.; *Takeda Oncology; University of Minnesota; University of Pittsburgh; University of Texas-MD Anderson; University of Wisconsin-Madison and Viracor Eurofins. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA), or any other agency of the U.S. Government. *Corporate members: Kristina Jacobs for administrative support.

PY - 2021/4

Y1 - 2021/4

UR - http://www.scopus.com/inward/record.url?scp=85105142269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105142269&partnerID=8YFLogxK

U2 - 10.1038/s41408-021-00472-w

DO - 10.1038/s41408-021-00472-w

M3 - Comment/debate

C2 - 33927193

AN - SCOPUS:85105142269

SN - 2044-5385

VL - 11

JO - Blood cancer journal

JF - Blood cancer journal

IS - 4

M1 - 82

ER -

Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis (Blood Cancer Journal, (2019), 9, 12, (97), 10.1038/s41408-019-0261-1)

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this